Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS
19 Jan 2021
byStephen Padilla
The efficacy and safety of long-term tildrakizumab are comparable and maintained without evidence of reduced durability of response through 148 weeks of treatment in patients with and without metabolic syndrome (MetS), results from two phase III trials have shown.
Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS
19 Jan 2021